Lv19
100 积分 2026-01-23 加入
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
7天前
已完结
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
7天前
已完结
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
7天前
已完结
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia
11天前
已完结
CD19 expression in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia pre‐ and post‐treatment with blinatumomab
11天前
已完结
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
12天前
已完结
Phase III Data Support Chemo-Free Approach to ALL
5个月前
已关闭
Phase III Data Support Chemo-Free Approach to ALL
5个月前
已关闭
Sustained Benefit of Blinatumomab in Infants With KMT2A -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics
5个月前
已关闭
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
5个月前
已完结
皖公网安备34019202002308
